Document:

EX-10.5

 EXHIBIT 10.5 
 SCICLONE PHARMACEUTICALS, INC. 
 EXECUTIVE SEVERANCE AGREEMENT 

This Executive Severance Agreement (the “Agreement”) is effective as of the first date of
employment by and between Hong Zhao (the “Executive”) and SciClone Pharmaceuticals, Inc., a Delaware corporation (the “Company”). 

RECITALS 
 A. The Executive
presently serves as Chief Executive Officer of China operations of the Company, and performs significant strategic and management responsibilities necessary to the continued conduct of the Company’s business and operations. 

B. The Board of Directors of the Company (the “Board”)
through its Compensation Committee has determined that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of the Executive of the Company.

 C. The Board believes that it is imperative to provide the Executive with certain severance benefits upon the
Executive’s termination of employment without Cause that will provide the Executive with enhanced financial security and provide sufficient incentive and encouragement to the Executive to remain with the Company. 

AGREEMENT 
 The Executive and
the Company agree as set forth below: 
 1. Terms of Employment. The Company and the Executive agree that the
Executive’s employment is based on the original offer letter and labor contract terms and that their employment relationship may be terminated by either party at any time, with or without Cause, and, if applicable, in accordance with
Section 2 below. If the Company terminates Executive’s employment without Cause, the Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided by this Agreement. During his employment
with the Company, the Executive agrees to devote his full business time, energy and skill to his duties with the Company. These duties shall include, but not be limited to, any duties consistent with the Executive’s position that may be
assigned to the Executive from time to time by the Company or the Board. 

  
 1 

 2. Severance Benefits Upon Termination without Cause. Subject to the limitations set
forth in Sections 3 and 4 below, if the Executive’s employment with the Company is terminated without Cause, then the Executive shall be entitled to receive, in addition to the compensation and benefits earned by the Executive through the
date of his or her termination, severance benefits as follows: 
 (a) The Executive shall be entitled to receive severance pay in
the form of continuation of Employee’s base salary in effect on Employee’s termination date for twelve (12) months following such termination date. These payments will be made on the Company’s ordinary payroll dates starting with
the first pay date after the termination date, and will be subject to standard payroll deductions and withholdings. 
 (b) The
Executive shall be entitled to receive a separation bonus equal to the gross amount of fifty percent (50%) of the average annual performance bonus paid to the Executive for the two (2) most recent fiscal years for which bonuses have been
paid prior to the termination date. If no or only one annual bonus has been paid at the time of termination the target bonus will be used as reference. 
 (c) The Company shall, if permitted under the Company’s existing health insurance plans, continue the Executive’s existing group health insurance coverage. If not so permitted, the Company shall
reimburse the Executive for any health insurance premiums paid by the Executive for continued group health insurance coverage. Such health insurance coverage or reimbursement of premiums shall continue until the earlier of (i) twelve
(12) months after the date of the Executive’s Involuntary Termination or (ii) the date on which the Executive commences New Employment. 
 3. Voluntary Resignation; Termination For Cause. 
 (a) If the
Employee’s employment terminates by reason of the Employee’s voluntary resignation (but not as a result of an Involuntary Termination) or as a result of the Employee’s termination for Cause, then the Employee shall not be entitled to
receive any severance pay or benefits under this Agreement. 
 (b) Disability; Death. If the Company terminates the
Executive’s employment as a result of the Executive’s Disability, or death, then the Executive shall not be entitled to receive any severance pay or benefits under this Agreement. 

4. Release of Claims; Resignation. The Executive’s entitlement to any severance pay or benefits under Section 2 is
conditioned upon the Executive’s execution and delivery to the Company of (a) a general release of known and unknown claims in the form attached hereto as Exhibit A and (b) a resignation from all of the Executive’s
positions with the Company, including from the Board and any committees thereof on which the Executive serves, in a form satisfactory to the Company. 
 5. Consulting Services. During the six (6) months following any termination without Cause for which the Executive receives the severance pay and benefits described in Section 2, the
Executive shall be retained by the Company as an independent contractor to provide consulting services to the Company at its request for up to eight (8) hours per week. These services shall include any reasonable requests for information or
assistance by the Company, including, but not limited to, the transition of the Executive’s duties. Such services shall be provided at mutually convenient times. For the actual provision of such services, the Company shall pay to the Executive
a consulting fee of $1,000 on a full eight hour day basis, pro-rated for the number of hours of service, plus reasonable out-of-pocket expenses (for example, travel and lodging). 

  
 2 

 6. Definition of Terms. The following terms referred to in this Agreement shall have
the following meanings: 
 (a) “Cause” shall mean any of the following: 

(i) the Executive’s theft, dishonesty, misconduct or falsification of any records of the Company, its successor, or any subsidiary
of the Company or its successor (collectively, the “Company Group”); 

(ii) the Executive’s misappropriation or improper disclosure of confidential or proprietary information of the Company Group;

 (iii) any intentional action by the Executive which has a material detrimental effect on the reputation or business of the
Company Group; 
 (iv) the Executive’s failure or inability to perform any reasonable assigned duties after written notice
from the Company Group of, and a reasonable opportunity to cure, such failure or inability; 
 (v) any material breach by the
Executive of any employment agreement between the Executive and the Company Group, which breach is not cured pursuant to the terms of such agreement; or 
 (vi) the Executive’s conviction of any criminal act which impairs the Executive’s ability to perform his or her duties for the Company Group. 

(b) “Disability” means the inability of the Executive, in the opinion of a qualified physician, to perform the
essential functions of the Executive’s position with the Company Group, with or without reasonable accommodation, because of the sickness or injury of the Executive. 
 (c) “New Employment” shall mean any employment obtained by the Executive after the termination of the Executive’s employment with the Company. 

7. Nonsolicitation. During his or her employment with the Company, and for a period of one (1) year following the termination
of his or her employment for any reason, the Executive shall not directly or indirectly recruit, solicit, or induce any person who on the date hereof is, or who subsequently becomes, an executive, sales representative or consultant of the Company,
to terminate his or her relationship with the Company. 
 8. Successors. 

(a) Company’s Successors. Any successor to the Company or to all or substantially all of the Company’s business and/or
assets shall be bound by this Agreement in the same manner and to the same extent as the Company. For all purposes under this Agreement, the term “Company” shall include any successor to the Company’s business and/or assets.

  
 3 

 (b) Executive’s Successors. All rights of the Executive hereunder shall inure to
the benefit of, and be enforceable by, the Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. The Executive shall have no right to assign any of his or her
obligations or duties under this Agreement to any other person or entity. 
 9. Notice. 

(a) General. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have
been duly given when personally delivered or when mailed by U.S. registered or certified mail, return receipt requested and postage prepaid. In the case of the Executive, mailed notices shall be addressed to the Executive at the home address which
he most recently communicated to the Company in writing. In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Secretary. 

(b) Notice of Termination. Any termination by the Company Group or the Executive of their employment relationship shall be
communicated by a written notice of termination to the other party. 
 10. Miscellaneous Provisions. 

(a) No Duty to Mitigate. The Executive shall not be required to mitigate the amount of any payment contemplated by this Agreement
(whether by seeking New Employment or in any other manner), nor shall any such payment be reduced by any earnings that the Executive may receive from any other source. 
 (b) Waiver. No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by the Executive and by an
authorized officer of the Company (other than the Executive). No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or
provision or of the same condition or provision at another time. 
 (c) Choice of Law. The validity, interpretation,
construction and performance of this Agreement shall be governed by the laws of the State of California. 
 (d)
Severability. The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect. 

(e) Arbitration. Any dispute, controversy or claim arising out of or relating to this contract, including the validity,
invalidity, breach or termination thereof, shall be settled by arbitration in Hong Kong under the Hong Kong International Arbitration Centre Administered Arbitration Rules in force with the Notice of Arbitration is submitted in accordance with these
rules . Judgment upon any decision or award rendered by the arbitrator may be entered in any court having jurisdiction over the matter. The Executive and the Company knowingly and willingly waive their respective rights to have any such disputes or
claims tried to a judge or jury. 

  
 4 

 (f) Prior Agreements; Controlling Agreement in the Case of a Change in Control. This
Agreement supersedes all prior understandings and agreements, whether written or oral, regarding the subject matter of this Agreement, provided, however, that the Change in Control Agreement dated March 15, 2013 (the “CIC
Agreement”) between Executive and Company shall remain in place and is not amended or waived in any way hereby. If Executive is entitled to receive severance benefits under the CIC Agreement, then the CIC Agreement shall be controlling.

 [Remainder of Page Left Intentionally Blank] 

  
 5 

 IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the
Company by its duly authorized officer, as of the day and year first above written. 
  

			
	SCICLONE PHARMACEUTICALS, INC.
		
	By:	 	/s/ Friedhelm Blobel
		 	FRIEDHELM BLOBEL, Ph.D.

  

	
	EXECUTIVE
	
	/s/ Hong Zhao
	HONG ZHAO

  
 6 

 Exhibit A 
 RELEASE 
 In exchange for the severance pay and benefits described in the
Executive Severance Agreement between SciClone Pharmaceuticals, Inc. (the “Company”) and me of my first date of employment (March 15, 2013) I hereby release the Company, its parents and subsidiaries, and their officers,
directors, employees, attorneys, stockholders, successors, assigns and affiliates, of and from any and all claims, liabilities, and causes of action of every kind and nature, whether known or unknown, based upon or arising out of any agreements,
events, acts, omissions or conduct at any time prior to and including the execution date of this Release, including, but not limited to: all claims concerning my employment with the Company or the termination of that employment; all claims pursuant
to any PRC Labor Contract Law and the regulations promulgated by the local government having jurisdiction over the employment. 

I am knowingly, willingly and voluntarily releasing any claims I may have under relevant local laws. I acknowledge that the consideration
given for the release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. 

I hereby waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect
to my release of any unknown claims I may have, and I affirm that it is my intention to release all known and unknown claims that I have or may have against the parties released above. 

  
 1 

 This Release contains the entire agreement between the Company and me regarding the subjects
above, and it cannot be modified except by a document signed by me and an authorized representative of the Company. 
  

							
	Date:
                            	 		 	 EXECUTIVE
  

		 		 	HONG ZHAO
			
		 		 	SCICLONE PHARMACEUTICALS, INC.
				
	 Date:
                            
	 		 	By:	 	 
				
		 		 	Its:	 	 

  
 2EX-10.6

 EXHIBIT 10.6 
 Friedhelm Blobel, Ph.D.  
 Executive Director 

CONFIDENTIAL 
 February 22, 2013

 Hong Zhao 
 30 F Shanghai Times
Square 
 No. 93 Huai Hai Zhong Road 
 Shanghai 200021 
 China 
 Dear Mr. Zhao, 
 Referring to the offer letter dated February 22, 2013 to
join SciClone Pharmaceuticals as CEO China Operations, I am pleased to offer you also a Sign-On Bonus in the amount of RMB 300,000 (three hundred thousand RMB). This Sign-On Bonus will be paid with the first regular payroll less applicable
withholding taxes. 
 Although this bonus will be paid at the time noted, it will not be fully earned until the first
anniversary of your employment start date. Should you voluntarily terminate your employment prior to the first anniversary of your employment start date, you shall be required to repay as of your termination date the full amount of the Sign-On
Bonus. 
  

	
	Sincerely,
	
	/s/ Friedhelm Blobel
	 Friedhelm Blobel, Ph.D.

Executive Director

	  
 For and on behalf of

NovaMed Pharmaceuticals (Shanghai)
 Co., Ltd. and
its affiliates

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]